At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 124 enrolled
Drug / intervention
Abicipar pegoldrug
Likely dose
Abicipar pegol 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating Abicipar pegol for Macular Degeneration. Completed, enrolled 124 participants across 37 sites.
Detailed Summary
The objective of this study is to evaluate abicipar pegol for safety and treatment effects in participants with neovascular age-related macular degeneration (AMD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartMay 2018
First PostedMay 2018
Primary CompletionFeb 2019
TodayJul 2026
First PostedMay 29, 2018
Enrollment StartMay 25, 2018
Primary CompletionFeb 27, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.1 years ago
Interventions
Abicipar pegoldrug
Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.